Maze Therapeutics Income Statement (2024-2025) | MAZE

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) 15.00M2.50M
Operating items
Research & Development (Quarter) 21.88M19.55M19.86M22.22M27.58M28.11M25.19M27.57M
Selling, General & Administrative (Quarter) 6.14M5.90M6.87M7.51M7.82M8.37M7.78M10.49M
Operating Expenses (Quarter) 28.01M25.45M26.73M29.73M35.40M36.47M32.97M38.06M
Operating Income (Quarter) -28.01M139.56M-24.23M-29.73M-35.40M-36.47M-32.97M-38.06M
EBIT (Quarter) -28.01M139.56M-24.23M-29.73M-35.40M-36.47M-32.97M-38.06M
Non-operating items
Interest & Investment Income (Quarter) 0.28M1.01M1.85M1.52M2.62M2.79M2.88M3.49M
Other Non Operating Income (Quarter) -4.76M0.22M-2.65M-1.64M
Net income details
EBT (Quarter) -27.73M140.78M-25.03M-29.85M-32.79M-33.68M-30.09M-34.57M
Tax Provisions (Quarter) 1.73M-0.28M-0.28M
Profit After Tax (Quarter) -32.49M139.06M-24.75M-29.58M-32.79M-33.68M-30.09M-34.57M
Income from Continuing Operations (Quarter) -27.73M139.06M-24.75M-29.58M-32.79M-33.68M-30.09M-34.57M
Consolidated Net Income (Quarter) -27.73M139.06M-24.75M-29.58M-32.79M-33.68M-30.09M-34.57M
Income towards Parent Company (Quarter) -27.73M139.06M-24.75M-29.58M-32.79M-33.68M-30.09M-34.57M
Net Income towards Common Stockholders (Quarter) -27.73M13.88M-24.75M-5.63M-32.79M-33.68M-30.09M-34.57M
Additional items
EPS (Basic) (Quarter) -13.915.92-10.25-2.07-1.15-0.77-0.66-0.60
EPS (Weighted Average and Diluted) (Quarter) -13.913.22-10.25-1.42-1.15-0.77-0.66-0.60
Shares Outstanding (Weighted Average) (Quarter) 2.34M2.39M2.38M2.40M28.63M36.25M45.78M42.98M
Shares Outstanding (Diluted Average) (Quarter) 2.34M4.31M2.42M2.73M28.63M36.25M39.46M42.98M
EBITDA (Quarter) -28.01M139.56M-24.23M-29.73M-35.40M-36.47M-32.97M-38.06M
Shares Outstanding (Quarter) 2.42M2.42M2.44M2.45M43.80M43.85M48.08M49.34M
Tax Rate (Quarter) 1.231.110.92